APA (7th ed.) Citation

Pellegrino, B., Tommasi, C., Serra, O., Gori, S., Cretella, E., Ambroggi, M., . . . Musolino, A. (2023). Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016). Journal for immunotherapy of cancer, 11(11), e007667. https://doi.org/10.1136/jitc-2023-007667

Chicago Style (17th ed.) Citation

Pellegrino, Benedetta, et al. "Randomized, Open-label, Phase II, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early HER2-positive Breast Cancer—Immun-HER Trial (GOIRC-01-2016)." Journal for Immunotherapy of Cancer 11, no. 11 (2023): e007667. https://doi.org/10.1136/jitc-2023-007667.

MLA (9th ed.) Citation

Pellegrino, Benedetta, et al. "Randomized, Open-label, Phase II, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early HER2-positive Breast Cancer—Immun-HER Trial (GOIRC-01-2016)." Journal for Immunotherapy of Cancer, vol. 11, no. 11, 2023, p. e007667, https://doi.org/10.1136/jitc-2023-007667.